Kymera Therapeutics Inc (KYMR)vsEli Lilly and Company (LLY)
KYMR
Kymera Therapeutics Inc
$74.13
-0.64%
HEALTHCARE · Cap: $7.09B
LLY
Eli Lilly and Company
$1,131.42
-0.32%
HEALTHCARE · Cap: $948.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 140255% more annual revenue ($72.25B vs $51.48M). LLY leads profitability with a 35.0% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 78/100 (B+).
KYMR
Avoid34
out of 100
Grade: F
LLY
Strong Buy78
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-56.8%
Fair Value
$52.46
Current Price
$74.13
$21.67 premium
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 55.5% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
ROE of -20.5% — below average capital efficiency
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : KYMR
The strongest argument for KYMR centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : KYMR
The primary concerns for KYMR are EPS Growth, Profit Margin, Piotroski F-Score.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Key Dynamics to Monitor
KYMR profiles as a hypergrowth stock while LLY is a growth play — different risk/reward profiles.
KYMR carries more volatility with a beta of 2.03 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 34/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kymera Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins by harnessing the body's own natural protein breakdown system. The company is headquartered in Watertown, Massachusetts.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?